La historia de Karen
Soy originaria de Nicaragua y ahora vivo en la soleada Barcelona. Hablo inglés y español, y formo parte del equipo de Estrategia Comercial en una empresa tecnológica. Actualmente estoy en remisión tras un diagnóstico de linfoma folicular grado 3A en 2024.
Siempre he valorado las relaciones significativas y me atrae profundamente el bienestar a través de la meditación, la danza extática, la lectura, la música y el contacto con la naturaleza.
Karen’s Story
I’m originally from Nicaragua and now based in sunny Barcelona. I speak English and Spanish, and I work in a tech company within the Commercial Strategy team. I’m currently in remission following a diagnosis of grade 3A follicular lymphoma in 2024.
I’ve always been someone who values meaningful connections and is deeply drawn to wellbeing through meditation, ecstatic dance, reading, music, and spending time in nature.
The FLF 2025 Global Patient Survey – what did we learn?
In October 2025, we conducted the FLF’s annual Global Patient Survey to better understand the challenges, concerns, and priorities of people living with follicular lymphoma. More than 1,000 people took part from over 50 countries worldwide – sharing their experiences across different stages of the disease and from healthcare systems around the world. These insights offer an important perspective on where support is working well and where further progress is needed.
Joanne’s Story
I was on a lunch break at work and had gone for a short walk with my friend and received a phone call from the GP surgery informing me that the biopsy I’d had of a swollen lymph node in my groin revealed I had Follicular lymphoma. I was in complete shock & felt that everything felt unreal. The rest of the day was a blur.
Tazemetostat in Follicular Lymphoma: What Patients Need to Know After the Recent Market Withdrawal
On 9th March came the announcement that tazemetostat (Tazverik) is being voluntarily withdrawn worldwide. Ipsen, the company that markets tazemetostat, made this decision after new safety findings emerged from the ongoing SYMPHONY 1 clinical trial, which indicated a possible increased risk of secondary blood cancers when the drug was used in a specific combination regimen (lenalidomide and rituximab, also referred to as R2).
Celebrating the Women Researchers Driving Progress in Follicular Lymphoma Research
This International Women’s Day the FLF and our global community are proud to celebrate and highlight the exceptional women whose scientific insight, dedication and innovation are driving progress in follicular lymphoma research.
Webinar: Your Health Data: How it Powers Research
Could your health data help improve care for people living with follicular lymphoma?
Watch our free webinar with lymphoma expert Dr Peter Martin, patient advocate Chris Carrigan, and FLF’s Chief Medical Officer Dr Mitchell Smith to learn how health data is helping shape the future of FL research and what it means for you.
Science simplified- Who needs treatment and when?
In this “Science Simplified” series, we’ll be sharing insights from the latest research presented at the American Society of Hematology (ASH) conference in December 2025.
Claire’s Story
Being a doctor and an oncology patient at the same time was a really strange experience. I was in disbelief for a long time. I just could not believe that these things that I had learnt about and read about for years were now happening to me. I had always felt so strong, invincible almost. It makes you realise how vulnerable we all really are.
Science simplified- how to make sense of research
In our upcoming “Science Simplified” series, we’ll be sharing insights from the latest research presented to us at the American Society of Hematology(ASH) conference . But before we explore that in detail, it is important to explain how we, and you, can read research critically.